Polyclonal Antibody specific for Transmembrane AMPA Receptor Protein (TARP)
JHU REF: [C12231]
Invention novelty: This technology is an anti-TARP [transmembrane alpha-amino-3-hydroxyl-5-isoxazolepropionate (AMPA) receptor protein] gamma 8 polyclonal antibody.
Value Proposition: In many neurological diseases, AMPA receptor function and structure are altered. This arrangement makes AMPA receptors potential therapeutic targets for clinical intervention. This technology, by interacting with AMPA receptor complexes, has several advantages:
• Research tool to study modulation of function of receptors, including gating and signaling
• Reagent specific to study regulation of AMPA receptor trafficking
Technical Details: Johns Hopkins researchers have developed a polyclonal antibody to a stargazin-like receptor regulatory protein. It has been found to play a pivotal role in AMPA receptor trafficking, messaging, and gating. It interacts with AMPA receptor complexes to induce modification and receptor signaling. This technology – anti-TARP gamma 8 pAb – could potentially help treatment and improve therapies of neurological diseases.
Looking for Partners: To develop & commercialize this technology for study of neurological disorders related to AMPA receptor modulation.
Stage of Development: Clinical
Publication(s)/Associated Cases: Not at this time
